Trial Profile
Phase II- pilot study of combination therapy with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] -daclizumab in HTLV-1 [human T-cell lymphotrophic virus-1] associated adult T-cell leukaemia/lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2005
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 04 Aug 2005 New trial record.